The hedge fund has met with Becton Dickinson's management and sent a letter to the board urging the divestiture of the unit, which supplies products for clinical and research laboratories. The size of Starboard's stake remains undisclosed.
Other shareholders have also begun advocating for the separation of the life sciences division, aligning with recent analyst reports suggesting that a spin-off could unlock significant value.
The Financial Times report writes that in December, Bank of America analysts noted that the disparity between Becton Dickinson's current valuation and its potential "sum of the parts" was becoming too substantial to ignore. They estimated that a split could boost the company's value by up to 30%.
In April 2022, Becton Dickinson spun off Embecta (NASDAQ:EMBC), a diabetes device maker, into a standalone entity.
In November, the company announced that it had decided to discontinue its insulin patch pump program and would initiate a restructuring plan.
In July, Embecta, a manufacturer of disposable insulin pen needles and syringes, said it is considering a potential sale following a significant drop in its share price since being spun off from health tech giant Becton, Dickinson.
Last week, Starboard Value decided not to pursue a proxy battle with Pfizer Inc (NYSE:PFE).
Starboard announced that it built a $1 billion stake in the pharmaceutical giant in October. The activist investor was reportedly planning to push for changes at the company given the stock's recent underperformance.
Price Action: BDX stock is up 1.03% at $250.16 at last check Monday.
Read Next:
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
